New cancer drug combo tested in early trial – but study stopped early

NCT ID NCT05904496

Terminated Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called BGB-30813, either alone or combined with the immunotherapy tislelizumab, in 44 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drugs shrank tumors. However, the study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGB-30813 (a DGKζ inhibitor) and tislelizumab (an immunotherapy drug)
What this could lead to: If it works, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This was a very early (phase 1) trial, so safety and effectiveness are not yet known. The trial was terminated early, meaning results may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Hackensack University Medical Center

Hackensack, New Jersey, 07601-1915, United States
Hospital Universitario Vall Dhebron

Barcelona, 08035, Spain
Jinan Central Hospital

Jinan, Shandong, 250013, China
Linear Clinical Research

Nedlands, Western Australia, 6009, Australia
Md Anderson Cancer Center

Houston, Texas, 77030-3907, United States
Monash Health

Clayton, Victoria, 3168, Australia
Next Oncology

San Antonio, Texas, 78229-6028, United States
Peter Maccallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Shandong Provincial Hospital

Jinan, Shandong, 250021, China
Start Madrid Fundacion Jimenez Diaz

Madrid, 28040, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.